Aspicio Therapeutics
Downingtown, US · Founded 2024 · Delaware corporation
Founders & leadership
MK
Michael KeaneExecutive
Reported raises · per SEC filings
Form D private placements$600K disclosed across 2 rounds · 2024–2026
▶$200KraisedJul 2026 · 2 investors · Other Health CareRule 506(b)
▶$200KraisedJul 2026 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael KeaneExecutive Officer, Director
- Offering amount
- $200K
- Amount sold
- $200K
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$400KraisedJun 2024 · 3 investors · Other Health CareRule 506(b)
▶$400KraisedJun 2024 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael KeaneExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $400K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Aspicio Therapeutics raised?
- Aspicio Therapeutics has disclosed $600K raised across 2 rounds.
- Where is Aspicio Therapeutics headquartered?
- Aspicio Therapeutics is headquartered in Downingtown, US.